American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section.
A number of important studies were presented at the CNS tumors section of the 2010 American Society of Oncology (ASCO) Annual Meeting. There was particular interest in a Phase II study showing that the mTOR inhibitor everolimus had significant activity in tuberous patients with subependymal giant cell astrocytomas. Two Phase III studies reported on the relative benefits of radiotherapy and chemotherapy in elderly patients with glioblastomas. Other studies focused on promising new agents such as XL184 and ANG1005.
Wen
Patrick Y
PY
Division of Cancer Neurology, Department of Neurology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. pywen@partners.org
D000368:Aged; D001254:Astrocytoma / Q000188:drug therapy*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D000068338:Everolimus; D005909:Glioblastoma / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014402:Tuberous Sclerosis / Q000188:drug therapy*
D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus